Role of Incretin Mimetics in Cardiovascular Outcomes and Other Classical Cardiovascular Risk Factors beyond Obesity and Diabetes Mellitus in Nondiabetic Adults with Obesity: a Meta-analysis of Randomized Controlled Trials.

Kamarullah W, Pranata R, Wiramihardja S, Tiksnadi BB

American journal of cardiovascular drugs : drugs, devices, and other interventions30 Nov 2024Cited by 2 (Europe PMC)

PMID39616304DOI10.1007/s40256-024-00695-9PepBankPUB-39616304

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of 3 tirzepatide trials, tirzepatide reduced the risk of major adverse cardiovascular events by 59% versus control groups.
In plain wordsIn a pooled analysis of 3 trials, tirzepatide lowered the risk of major heart events compared with control groups.
Peptide
Tirzepatide
Outcome
DecreaseMACE risk
Study
n: not reported in source
Comparator
Control groups
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
MACE risk ratio
0.41 ratio
tirzepatide
Source sentences
Summary
59% for tirzepatide [RR 0.41 (95% CI 0.18-0.92); P = 0.03; I² = 0%, P-heterogeneity = 0.96].
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 11 eligible randomized controlled trials (RCTs) comprising 8 GLP-1 RA trials and 3 dual GLP-1 RA/GIP (tirzepatide) trials were included.
Report a problemFND-3961630401

Studies that did not test the peptide alone4

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with obesity, pooled incretin mimetics (GLP-1 RA and tirzepatide) substantially reduced body weight versus control groups.
In plain wordsIn adults with obesity, pooled GLP-1 and related drugs lowered body weight compared with control groups.
Peptide
Tirzepatide
Outcome
DecreaseBody weight (pooled incretin mimetics)
Study
n: not reported in source
Comparator
Control groups
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Incretin mimetics also substantially reduced BW
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 11 eligible randomized controlled trials (RCTs) comprising 8 GLP-1 RA trials and 3 dual GLP-1 RA/GIP (tirzepatide) trials were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3961630402
03HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with obesity, pooled incretin mimetics (GLP-1 RA and tirzepatide) substantially reduced blood pressure versus control groups.
In plain wordsIn adults with obesity, pooled GLP-1 and related drugs lowered blood pressure compared with control groups.
Peptide
Tirzepatide
Outcome
DecreaseBlood pressure (pooled incretin mimetics)
Study
n: not reported in source
Comparator
Control groups
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Incretin mimetics also substantially reduced BW, BP, and improved lipid panel measures.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 11 eligible randomized controlled trials (RCTs) comprising 8 GLP-1 RA trials and 3 dual GLP-1 RA/GIP (tirzepatide) trials were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3961630403
04HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In adults with obesity, pooled incretin mimetics (GLP-1 RA and tirzepatide) improved lipid panel measures versus control groups.
In plain wordsIn adults with obesity, pooled GLP-1 and related drugs improved blood fat measures compared with control groups.
Peptide
Tirzepatide
Outcome
IncreaseLipid panel (pooled incretin mimetics)
Study
n: not reported in source
Comparator
Control groups
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Incretin mimetics also substantially reduced BW, BP, and improved lipid panel measures.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 11 eligible randomized controlled trials (RCTs) comprising 8 GLP-1 RA trials and 3 dual GLP-1 RA/GIP (tirzepatide) trials were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3961630404
05HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In adults with obesity, pooled incretin mimetics (GLP-1 RA and tirzepatide) increased the risk of adverse events, specifically gastrointestinal disorders.
In plain wordsIn adults with obesity, pooled GLP-1 and related drugs raised the risk of stomach and bowel side effects compared with control groups.
Peptide
Tirzepatide
Outcome
IncreaseGastrointestinal adverse events (pooled incretin mimetics)
Study
n: not reported in source
Comparator
Control groups
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
However, there was an increased risk of adverse events, specifically gastrointestinal disorders within the incretin mimetics subset.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 11 eligible randomized controlled trials (RCTs) comprising 8 GLP-1 RA trials and 3 dual GLP-1 RA/GIP (tirzepatide) trials were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3961630405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.